Are rotavirus vaccines a good investment for middle-income countries?

Middle-income countries not eligible for support from Gavi, the Vaccine Alliance, have been slow to introduce rotavirus vaccines, largely due to cost concerns. A PATH analysis shows that, in most cases, rotavirus vaccination is likely to be highly cost-effective and beneficial for these countries.

Authors